Immunomedics Announces Expanded Phase 1/2 Trials Which Confirm Activity, Good Safety Profile of IMMU-132
December 12, 2014 at 08:31 AM EST
Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's novel investigational antibody-drug ...